Alumis (ALMS) Non-Current Deffered Revenue (2025)
Alumis' (ALMS) quarterly Non-Current Deffered Revenue came in at $2.6 million in Q4 2025, up 34.31% quarter-over-quarter from $1.9 million in Q3 2025.
Powered by 
Analysis
Alumis (ALMS) Non-Current Deffered Revenue (2025) Analysis & Trends
Alumis (ALMS) has reported Non-Current Deffered Revenue for 1 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $2.6 million in Q4 2025; TTM through Dec 2025 was $2.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.6 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $2.6 million for Q4 2025 at Alumis, up from $1.9 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $2.6 million in Q1 2025 and troughed at $1.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 147.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Alumis | 966.94 Mn | 464.65 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 2.61 Mn |
| Mar 31, 2025 | 2.61 Mn |